Mahendra Shah
Vivo Ventures partner Shah becomes the sixth board member for Essentialis, which focusses on development of treatment for cardiovascular and metabolic disease.
Prior to serving for Vivo Ventures, he was CEO for several biopharmas, including Nextwave Pharmaceuticals Pediatric, which he founded in 2005.
“Essentialis expects to release its Phase IIb trial data for DCCR in the coming weeks. As we prepare to begin a new chapter with an exciting new compound for further evaluation, board members with Dr. Shah's range of experience will advance our development objectives,” said Stuart Collinson, Essentialis.